NCT05646576Recruiting
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups. The names of the study intervention groups involved in this study are: * Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care) Participation in this research study is expected to last for up to 2 years. It is expected that about 90 people will take part in this research study.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 2 Dec 2022
- Start date
- 30 Dec 2022
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT05646576
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 30 Dec 2022 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Already receiving palliative care (PC).
Other illness
- Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment.
Who the study is looking for
- Age 18 years or older.
- Ability to complete surveys in English or with assistance of an interpreter.
- Diagnosis of a hematologic malignancy.
- Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Cancer Center Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.